Literature DB >> 16005082

Opposing actions of fibroblast growth factor-2 on early and late oligodendrocyte lineage cells in vivo.

A M Butt1, J Dinsdale.   

Abstract

In vitro studies indicate that fibroblast growth factor 2 (FGF2) has diverse effects on cells of the early and late oligodendrocyte lineage. Here, we have examined this in vivo by comparing the actions of FGF2 on the developing and developed anterior medullary velum (AMV) of postnatal rats. FGF2, or saline vehicle in controls, was administered into the cerebrospinal fluid of anaesthetised rats between postnatal day (P)6 and P9 either for 1 day (1d), 2d, or 3d, and AMV were analysed at P8 or P9. Immunolabelling for NG2 was used to identify oligodendrocyte progenitor cells (OPCs) and Rip for premyelinating and myelin-forming oligodendrocytes. At P6-9, the AMV was clearly demarcated into myelinated caudal and premyelinated rostral areas. The caudal AMV was populated by differentiated myelin-forming oligodendrocytes and 'adult' OPCs, whilst the rostral AMV contained mixed populations of 'perinatal' OPCs, and both premyelinating and myelin-forming oligodendrocytes. Administration of FGF2 resulted in the accumulation of OPCs in both the developing and developed AMV. Notably, FGF2 had a bipartite action on premyelinating oligodendrocytes, at first dramatically expanding their population throughout the premyelinated and myelinated AMV, but subsequently causing the loss of these previously generated cells. In addition, FGF2 induced the loss of existing myelin-forming oligodendrocytes in the developed AMV, and arrested the generation of new myelin-forming cells in the developing AMV. This study provides evidence that FGF2 has opposing positive and negative actions on early and late oligodendrocyte lineage cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005082     DOI: 10.1016/j.jneuroim.2005.05.015

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

Review 1.  Oligodendrocyte Development and Plasticity.

Authors:  Dwight E Bergles; William D Richardson
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-08-20       Impact factor: 10.005

2.  Neuroprotective role of fibroblast growth factor-2 in experimental autoimmune encephalomyelitis.

Authors:  Andrea Rottlaender; Hannah Villwock; Klaus Addicks; Stefanie Kuerten
Journal:  Immunology       Date:  2011-05-13       Impact factor: 7.397

Review 3.  Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology.

Authors:  Li-Jin Chew; Cynthia A DeBoy
Journal:  Neuropharmacology       Date:  2015-06-24       Impact factor: 5.250

Review 4.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Polarizing receptor activation dissociates fibroblast growth factor 2 mediated inhibition of myelination from its neuroprotective potential.

Authors:  Katja Thümmler; Eran Rom; Thomas Zeis; Maren Lindner; Sarah Brunner; John J Cole; Diana Arseni; Steve Mücklisch; Julia M Edgar; Nicole Schaeren-Wiemers; Avner Yayon; Christopher Linington
Journal:  Acta Neuropathol Commun       Date:  2019-12-19       Impact factor: 7.801

6.  Progenies of NG2 glia: what do we learn from transgenic mouse models ?

Authors:  Qilin Guo; Anja Scheller; Wenhui Huang
Journal:  Neural Regen Res       Date:  2021-01       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.